Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SpikoGen immunogenicity and safety in children and adults
NCT05231590Phase 3Completed
- Sponsor
- CinnaGen
- Start
- Feb 2022
- Primary completion
- Apr 2022
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of SpikoGen in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by CinnaGen. Primary endpoint: Percentage of participants with seroconversion for SARS-CoV-2 neutralizing antibodies. Started Feb 2022; status: completed.
02
Drugs
SpikoGen
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05231590.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05231590.